Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized versus intravenous amikacin in ventilator-associated pneumonia
IRCT20221222056890N3Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amikacin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Apr 2026; status: recruiting.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20221222056890N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221222056890N3.